-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25

Benzinga·08/13/2026 14:12:08
Listen to the news
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $37 to $25.